Genetic polymorphisms of CYP2C9/CYP2C19 in chronic obstructive pulmonary disease
preprint
OA: closed
CC-BY-4.0
Abstract
Abstract Background : Chronic obstructive pulmonary disease (COPD) has a high incidence in elderly and significantly affects the quality of life. CYP2C9 and CYP2C19 have an important role in tobacco-related diseases and inflammatory reaction. Thus, in this study we aims to investigate the association between CYP2C9 / CYP2C19 polymorphisms and the risk of COPD. Methods: A total of 821 subjects were recruited which including 313 COPD patients and 508 healthy controls. Seven SNPs of CYP2C9 / CYP2C19 were selected for genotyping. The Odds ratios (ORs) and 95% confidence interval (95% CI) were calculated using a logistic regression analysis to evaluate the association between COPD risk and CYP2C9 / CYP2C19 polymorphisms. Results: The rs9332220 of CYP2C9 “A” allele was associated with reducing COPD risk (OR = 0.64, 95% CI = 0.43 – 0.94, p = 0.021). And rs11853758 “G” allele carrier could significantly decrease 0.35-fold COPD risk compared with T allele carrier (OR = 0.65, 95% CI = 0.45 – 0.96, p = 0.027). Furthermore, gender-based stratification analysis showed that rs9332220 and rs11853758 polymorphisms were associated with risk of COPD in males. Conclusions: Our study firstly reported the effects of CYP2C9 and CYP2C19 genetic variants on COPD risk. We found that rs9332220 in CYP2C9 and rs11853758 in CYP2C19 were associated with a reduced susceptibility to COPD.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-05-19T01:45:01.086888+00:00
- unpaywall
- last seen: 2026-05-29T02:00:03.542394+00:00
License: CC-BY-4.0